Metformin and risk of cardiovascular disease.

Metformin and risk of cardiovascular disease.

Bibliographic Details
Main Authors:	Turner, R, Holman, R
Format:	Journal article
Language:	English
Published:	1999

Similar Items

METFORMIN IN THE MANAGEMENT OF TYPE-2 DIABETES - REPLY
by: Holman, R, et al.
Published: (1989)

Risk of antidepressant initiation among users of cardiovascular agents and metformin.
by: Ivana Bojanić, et al.
Published: (2023-04-01)

Metformin reduces the risk of developing influenza A virus related cardiovascular disease
by: Han Sol Lee, et al.
Published: (2023-10-01)

Metformin adherence and the risk of cardiovascular disease: a population-based cohort study
by: Shun-Fan Yu, et al.
Published: (2023-04-01)

Cardiovascular Effects of Metformin
by: B. T. Kurmanbekova, et al.
Published: (2022-03-01)

UKPDS - 6-YEAR TRIAL OF SULFONYLUREA, INSULIN AND METFORMIN THERAPY IN TYPE-2 DIABETIC-PATIENTS WITH DIET FAILURE
by: Cull, C, et al.
Published: (1995)

Metformin as first choice in oral diabetes treatment: the UKPDS experience.
by: Holman, R
Published: (2007)

Estimating cardiovascular disease risk for individuals with Type 2 diabetes: the new UKPDS Risk Engine
by: Coleman, R, et al.
Published: (2007)

Metformin and mortality. Reply to Lund SS [letter]
by: Stevens, R, et al.
Published: (2013)

Metformin and mortality. Reply to Lund SS [letter].
by: Stevens, R, et al.
Published: (2013)

UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
by: Wright, A, et al.
Published: (1998)

Risk of anaemia with long-term metformin use in a community setting
by: Donnelly, L, et al.
Published: (2017)

From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease
by: Anastasia V. Poznyak, et al.
Published: (2022-08-01)

BIOCHEMICAL RISK-FACTORS FOR CARDIOVASCULAR-DISEASE IN NEWLY-DIAGNOSED TYPE-II DIABETIC-PATIENTS AND AGE-MATCHED SUBJECTS
by: Turner, R, et al.
Published: (1993)

Impact of personalized cardiovascular disease risk estimates on physical activity-a randomized controlled trial.
by: Price, H, et al.
Published: (2011)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49)
by: Turner, R, et al.
Published: (1999)

Metformin-Insulin versus Metformin-Sulfonylurea Combination Therapies in Type 2 Diabetes: A Comparative Study of Glycemic Control and Risk of Cardiovascular Diseases in Addis Ababa, Ethiopia
by: Gebrie D, et al.
Published: (2021-07-01)

Cardiovascular endocrinology: First-time heart failure increases risk of diabetes mellitus
by: Holman, R
Published: (2014)

Cardiovascular endocrinology: First-time heart failure increases risk of diabetes mellitus.
by: Holman, R
Published: (2014)

Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin
by: Malcolm J. Borg, et al.
Published: (2020-11-01)

Metformin Protects Cardiovascular Health in People With Diabetes
by: Chong Chen, et al.
Published: (2022-07-01)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
by: Turner, R, et al.
Published: (1999)

Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
by: Simmons, R, et al.
Published: (2008)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
by: Califf, R, et al.
Published: (2003)

A cardiovascular risk calculator for type 2 diabetes
by: Coleman, R, et al.
Published: (2005)

Coronary heart disease and risk factors in NIDDM--experience from the United Kingdom Prospective Diabetes Study.
by: Turner, R, et al.
Published: (1997)

Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47).
by: Adler, A, et al.
Published: (1999)

The hypoglycaemic action of metformin.
by: Frayn, K, et al.
Published: (1971)

HYPOGLYCAEMIC ACTION OF METFORMIN
by: Frayn, K, et al.
Published: (1971)

Cardiovascular effects of metformin: focus on adipose tissue metabolism
by: Olga V. Gruzdeva, et al.
Published: (2022-09-01)

Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia
by: Wiebe M. C. Top, et al.
Published: (2022-03-01)

Improving glucose control and cardiovascular risk in general practice Type 2 diabetes.
by: Potts, N, et al.
Published: (2003)

Frequency of abnormal glucose tolerance and the metabolic syndrome in people at increased cardiovascular disease risk screened for the NAVIGATOR trial
by: Holman, R, et al.
Published: (2003)

Possible prevention of type 2 diabetes with acarbose or metformin over three years
by: Citroen, H, et al.
Published: (2000)

Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus
by: Tian Li, et al.
Published: (2021-01-01)

Diabetes, use of metformin, and the risk of meningioma.
by: Corinna Seliger, et al.
Published: (2017-01-01)

Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort.
by: Simmons, R, et al.
Published: (2009)

Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies.
by: Clarke, R, et al.
Published: (2001)

Metformin in skin diseases
by: Damian Kadylak, et al.
Published: (2021-05-01)

Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial.
by: de Barros e Silva, P, et al.
Published: (2014)